All News

Heel, pain,enthesitis,achilles

MSK Symptoms from Dupilimab, an IL-4/13 Inhibitor

d Jack Cush, MD

A new MSK syndrome of inflammatory enthesitis/arthritis/tenosynovitis has been described in atopic dermatitis (AD) patients treated with the IL-4 receptor antagonist, dupilumab.

Read Article
psA.fil_.Hands_.jpg

Brepocitinib in Active Psoriatic Arthritis

d Jack Cush, MD

Brepocitinib is a novel tyrosine kinase 2/Janus kinase 1 inhibitor and has been studied in patients with moderately-to-severely active psoriatic arthritis (PsA), showing impressive efficacy at both 16 weeks and 52 weeks.

Read Article
vasculitis.Churg-Strauss_syndrome.wikipedia.jpg

Evidence-Based Guidelines for EGPA

d Jack Cush, MD

Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare form of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis, affecting between 10 and 14 cases per million globally. This adult disorder has a mean age at diagnosis of nearly 50 years and affects both sexes equally, presenting with pulmonary symptoms (asthma), eosinophilia and granulomatous or vasculitic involvement of several organs. A multidisciplinary, multinational European group has developed evidence-based, guidelines for the diagnosis and management of EGPA, intended to include recent advances.

Read Article
pain.jpg

RELIEF Trial: Sublingual Cyclobenzaprine in Fibromyalgia

d MedPage Today

Fibromyalgia patients hoping to see a more effective and convenient formulation of cyclobenzaprine at their local pharmacies must wait for an ongoing phase III trial -- the product's third -- to finish, as the first two delivered mixed results.

Read Article
PSS.scleroderma.arthritis.contractures

Juvenile and Adult-onset Scleroderma Differ

d Jack Cush, MD

A retrospecitve cohort comparision of juvenile (jSSc) and adult-onset (aSSc) systemic sclerosis (SSc) are both rare but present differently.  

Read Article
ICYMI: Our old friend, hydroxychloroquine https://t.co/NouJayD0T3 https://t.co/lRBl0UQuY3

Links:

Dr. John Cush RheumNow ( View Tweet)
Conaghan shares unpublished data from PROMOTE study at #RNL2023 Early data shows MTX benefits pain in patients w/ OA, particularly more metabolically active. Looking forward to more data on this-- https://t.co/Zfh7CbqvPi https://t.co/kIYKRFtUX2

Links:

Dr. John Cush RheumNow ( View Tweet)
Metanalysis of 38 studies(458,256 pts). Diabetes was seen in 19% of hyperuricemic and 16.7% of gout pts - an even higher DM prevalence was seen in North America (20.7%) https://t.co/AYVWaditxG https://t.co/T4fedCSpx1

Links:

Dr. John Cush RheumNow ( View Tweet)
Matched cohort study of 67,598 German primary care Pts shows gout have incr risk of breast cancer (4.5% gout vs 3.7% non-gout; HR: 1.17; 1.05-1.31). Association only seen under age 50 (HR: 1.58; 1.10-2.27), but notin women over 50 yrs https://t.co/pl6gH2GyZQ https://t.co/VR8kuumhNv

Links:

Dr. John Cush RheumNow ( View Tweet)
What happens to PsA in pregnancy? 1/3 with mod-severe disease Little evidence of change of disease activity in pregnancy Disease may increase post-partum Christina Chambers @mothertobaby #RNL2023 @RheumNow https://t.co/0QAxhHb45u https://t.co/zb0YSaqiOf

Links:

Dr. John Cush RheumNow ( View Tweet)
DMARDs/TNF for PMR: MTX- initial benefit, but no 5 year steroid sparing effect Infliximab - no benefit Lef - some benefit in case series Robert Spiera #RNL2023 @RheumNow https://t.co/d7BpmxFfct https://t.co/jLJDPuMtD3

Links:

Dr. John Cush RheumNow ( View Tweet)
Is there role for MTX in GCA Favorable results in a meta-analysis with NNT 11 to prevent 1 cranial relapse BUT: limitations of meta-analysis, short follow-up, dose response not evaluated Robert Spiera at #RNL2023 @RheumNow https://t.co/lucAWypvr7 https://t.co/W604xXesaI

Links:

Dr. John Cush RheumNow ( View Tweet)
#RNL2023 Rob Spiera: I often use aspirin a day, especially if cranial complications and no contra-indications" No prospective studies, 2 large retrospective studies suggesting benefit @RheumNow https://t.co/V8C43LN5wl https://t.co/2focIzWhPP

Links:

Dr. John Cush RheumNow ( View Tweet)
Lit review of 2236 articles found only 28 w/ Post-COVID autoimmune Dx (64% F; age 51 yrs) - that included 11 (39) IIM (w/ 4 DM); 7 (25%) SLE; 4 (14%) anti-synthetase syndrome; 4 (14%) SSc; 1 lupus/MCTD overlap. Mean onset 23.7 d post COVID https://t.co/jtRaqIBGH1 https://t.co/WilcRFNAL9

Links:

Dr. John Cush RheumNow ( View Tweet)
Review of the etiology of Polyserositis (14 pts, 23 articles): most common - neoplasia (26.3%; Lung Lymphoma; ovarian; pancreatic), autoimmune (16.7% - SLE, AOSD) & infections (12.3%; coxackie, CMV, mTB). https://t.co/Bubd99ETgu https://t.co/VbiPB0y7pv

Links:

Dr. John Cush RheumNow ( View Tweet)
Disappointing Secondary Use of Newer Therapies in Psoriatic Arthritis Analysis of patient data from five Nordic registries shows that the uptake of newer b/tsDMARDs in PsA was mainly in biologic-experienced patients. https://t.co/SP9ZKGvM0J https://t.co/1tfSiWHYfl

Links:

Dr. John Cush RheumNow ( View Tweet)
FDA approves a NGF inhbitor bedinvetmab (Librela) to treat osteoarthritis in Dogs!. Recently FDA approved NGF inhibitor cats w/ OA --- Yet 4 different NGF inhibitors failed in their development for human OA - are cats & dogs treated better than us? https://t.co/Tbca0PiEL2 https://t.co/Y7mViSa5J4

Links:

Dr. John Cush RheumNow ( View Tweet)
One in Ten is Bad! This week on the Podcast Dr. Jack Cush reviews the news and journal articles, including the risks of dying, developing RA or autoimmune disease! https://t.co/5SXPotfhs0 https://t.co/jXwsWoltsy

Links:

Dr. John Cush RheumNow ( View Tweet)
RheumThoughts: Giving Good Care in Diversity takes Time Dr. Yvonne Sherrer and second-year fellow Dr. Corin Agoris discuss a case where extended time led to improved patient outcomes. https://t.co/NRHBwHLqSi https://t.co/nj8eaGiU50

Links:

Dr. John Cush RheumNow ( View Tweet)
Watch: Meetings should be like Oktoberfest https://t.co/pZGOYXINir https://t.co/RIXmpRztaL

Links:

Dr. John Cush RheumNow ( View Tweet)
×